Calvin Sandra 4
4 · Travere Therapeutics, Inc. · Filed Feb 12, 2025
Insider Transaction Report
Form 4
Calvin Sandra
SVP, CHIEF ACCOUNTING OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-02-11$17.44/sh+10,000$174,400→ 73,654 total - Exercise/Conversion
Common Stock
2025-02-11$17.96/sh+10,000$179,600→ 73,654 total - Exercise/Conversion
Common Stock
2025-02-11$15.46/sh+15,000$231,900→ 78,654 total - Sale
Common Stock
2025-02-11$25.00/sh−9,244$231,100→ 54,410 total - Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−10,000→ 0 totalExercise: $16.23Exp: 2026-05-19→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−10,000→ 0 totalExercise: $17.44Exp: 2027-05-17→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−10,000→ 0 totalExercise: $17.96Exp: 2029-05-09→ Common Stock (10,000 underlying) - Exercise/Conversion
Employee stock option (right to buy)
2025-02-11−15,000→ 0 totalExercise: $15.46Exp: 2030-01-31→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2025-02-11$16.23/sh+10,000$162,300→ 73,654 total - Sale
Common Stock
2025-02-11$25.00/sh−10,000$250,000→ 63,654 total - Sale
Common Stock
2025-02-11$25.00/sh−10,000$250,000→ 63,654 total - Sale
Common Stock
2025-02-11$25.00/sh−10,000$250,000→ 63,654 total - Sale
Common Stock
2025-02-11$25.00/sh−15,000$375,000→ 63,654 total
Footnotes (6)
- [F1]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of May 19, 2026.
- [F2]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of May 17, 2027.
- [F3]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of May 9, 2029.
- [F4]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of January 31, 2030.
- [F5]This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
- [F6]The stock option is fully vested and exercisable.